Holen Sie sich die Stockscreener-App
3.65
3.99%
0.14
Handel nachbörslich:
3.65
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
FY2025 Earnings Forecast for AMLX Issued By Leerink Partnrs - MarketBeat
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Update - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - Markets Insider
JPMorgan Chase & Co. Purchases 83,048 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - Markets Insider
2025-01-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation | NDAQ:AMLX | Press Release - Stockhouse Publishing
FDA lifts clinical hold on Amylyx ALS drug study - MSN
FDA clears Amylyx to resume ALS drug trial in North America - MSN
Fierce Biotech Names Amylyx Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2020 - Marketscreener.com
Clinical hold lifted from Phase 1 trial of ALS therapy AMX0114 - ALS News Today
FDA lifts clinical hold on Amylyx’s Phase I ALS trial - MSN
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets - BioSpace
Amylyx Says FDA Lifts Clinical Hold on ALS-Drug Trial - MarketWatch
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis - Business Wire
Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $7.33 - MarketBeat
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - AccessWire
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - AccessWire
Amylyx Pharmaceuticals Prices of Public Offering of Common Stock - citybiz
Amylyx stock dips after pricing $60M stock offering - MSN
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock - BioSpace
Amylyx Pharmaceuticals Announces Common Stock Offering to Fuel Commercialization Plans - StockTitan
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire
Amylyx Pharmaceuticals co-CEO Justin Klee sells $30,201 in stock By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - AccessWire
Justin B. Klee Sells 7,471 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock - MarketBeat
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells shares worth $30,232 By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells shares worth $30,232 - Investing.com
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
ALS drugs from Denali, Calico come up short, marking more failures for Healey trial - BioPharma Dive
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - AccessWire
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer - citybiz
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
AMYLYX PHARMACEUTICALS 48 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Amylyx - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - AccessWire
Amylyx and Gubra collaborate to develop long-acting GLP-1 receptor antagonist - BioWorld Online
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Up 8.3% in December - MarketBeat
Amylyx inks deal with Gubra for diabetes treatment By Investing.com - Investing.com Nigeria
Amylyx inks deal with Gubra for diabetes treatment - Investing.com India
Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey
Gubra A/S Announces New Collaboration with Amylyx Pharmaceuticals, Inc. to Develop a Novel Long-Acting GLP-1 Receptor Antagonist - Marketscreener.com
Amylyx Partners with Gubra for GLP-1 Antagonist - TipRanks
Gubra in collaboration with Amylyx to develop long-acting GLP-1 antagonists - Marketscreener.com
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):